体外研究 (In Vitro) |
Hexane-2,5-dione (16-256 μM; 24 h) 可诱导人原代卵巢颗粒细胞发生与凋亡一致的形态学改变。 Hexane-2,5-dione (16-256 μM; 24 h) 可诱导原代人卵巢颗粒细胞发生剂量依赖性凋亡。 Hexane-2,5-dione (64-256 μM; 24 h) 以剂量依赖的方式下调原代人卵巢颗粒细胞中 BCL-2 mRNA 的表达,并上调 BAX 和 CASPASE-3 mRNA 的表达。 Hexane-2,5-dione (64-256 μM; 24 h) 在原代人卵巢颗粒细胞中以剂量依赖的方式下调 BCL-2 蛋白,并上调 BAX 和活化型 CASPASE-3 (p17 亚基) 蛋白。 2,5-Hexanedione (100 mM; 16 h) 可修饰纯化的牛脑微管蛋白,形成一种具有增强成核活性的促组装组分,表现为组装临界浓度降低 19 倍,且 α-微管蛋白结构发生改变。 2,5-Hexanedione (2,5-HD) 可在体外交联微管,从而降低其驱动基于驱动蛋白的运输的能力。 Hexane-2,5-dione (20-60 mM; 24 h) 可诱导大鼠卵巢颗粒细胞发生 G0/G1 期细胞周期阻滞,同时伴随细胞周期相关基因 p21、Cdk2 和 Ccnd1 的表达改变。 Hexane-2,5-dione (40-60 mM; 24 h) 可改变大鼠卵巢颗粒细胞中凋亡相关蛋白的表达,下调 Bcl-2 并上调 Bax、Caspase3 及 Caspase9。 Hexane-2,5-dione (60 mM; 24 h) 可改变大鼠卵巢颗粒细胞的 mRNA 和 miRNA 表达谱,差异表达基因在细胞周期和 Wnt/β-catenin 信号通路中显著富集。 Hexane-2,5-dione (20-60 mM; 24 h) 可剂量依赖性地抑制大鼠卵巢颗粒细胞中的 Wnt/β-catenin 信号通路,降低关键受体与转录因子的 mRNA 表达水平,并改变 β-catenin、GSK3β、p-β-catenin 及 Dvl3 的蛋白表达。 Hexane-2,5-dione (20-60 mM; 24 h) 可呈剂量依赖性降低大鼠卵巢颗粒细胞中 β-catenin 的核定位。 Hexane-2,5-dione (10 mM; 6-12 h) 可降低 COV434 人卵巢颗粒细胞的细胞活力。 Hexane-2,5-dione (10-160 mM; 6-12 h) 对大鼠卵巢颗粒细胞的活力无显著影响。 Hexane-2,5-dione (10-20 mM; 6 h) 可剂量依赖性地抑制人卵巢颗粒细胞瘤 COV434 细胞中 β-catenin/TCF 的转录活性。 Hexane-2,5-dione (20-60 mM; 24 h) 可改变大鼠卵巢颗粒细胞中 Wnt 通路相关 miRNA 的表达,下调 rno-miR-214-3p、rno-miR-138-5p、rno-miR-199a-3p、rno-miR-145-5p 及 rno-miR-143-3p。
Apoptosis Analysis
| Cell Line: |
primary human ovarian granulosa cells |
| Concentration: |
16; 64; 256 μM |
| Incubation Time: |
24 h |
| Result: |
Induced morphological changes consistent with apoptosis in primary human ovarian granulosa cells. Induced dose-dependent apoptosis. Showed total apoptotic rates reaching 7.8%, 26.8%, and 56.3%, at 16, 64, 256 μM, respectively. |
Real Time qPCR
| Cell Line: |
primary human ovarian granulosa cells |
| Concentration: |
16; 64; 256 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced BCL-2 mRNA and increased BAX and CASPASE-3 mRNA in a dose-dependent manner. Showed no no significant effect on these gene levels at 16 μM. |
Western Blot Analysis
| Cell Line: |
primary human ovarian granulosa cells |
| Concentration: |
16; 64; 256 μM |
| Incubation Time: |
24 h |
| Result: |
Downregulated BCL-2 protein and upregulated BAX and active CASPASE-3 (p17 subunit) protein in a dose-dependent manner. Showed no no significant effect on these protein levels at 16 μM.
|
Cell Viability Assay
| Cell Line: |
COV434 human ovarian granulosa cells |
| Concentration: |
10; 20; 40; 80; 160 mM |
| Incubation Time: |
6 h, 12 h |
| Result: |
Reduced cell viability in COV434 cells with 10 mM treatment after 6 h and 12 h. |
Cell Cycle Analysis
| Cell Line: |
rat ovarian granulosa cells |
| Concentration: |
20; 40; 60 mM |
| Incubation Time: |
24 h |
| Result: |
Induced G0/G1 phase cell cycle arrest. Increased the proportion of cells in G0/G1 phase. Decreased the proportion of cells in S phase.
|
Real Time qPCR
| Cell Line: |
rat ovarian granulosa cells |
| Concentration: |
20; 40; 60 mM |
| Incubation Time: |
24 h |
| Result: |
Altered expression of cell cycle-related genes p21, Cdk2, and Ccnd1. |
Western Blot Analysis
| Cell Line: |
rat ovarian granulosa cells |
| Concentration: |
20; 40; 60 mM |
| Incubation Time: |
24 h |
| Result: |
Decreasing Bcl-2 and increased Bax, Caspase3, and Caspase9 levels. |
|
体内研究 (In Vivo) |
Hexane-2,5-dione (2.5-3.5 mmol/kg/天;腹腔注射;每周 5 天;持续 17-38 天) 可在成年雄性 Wistar 大鼠中诱发严重神经毒性和睾丸损伤。 Hexane-2,5-dione (2-6 mmol/kg/天;经饮水口服;3-5 周) 可通过破坏支持细胞微管功能、减少生精小管液生成、诱导生殖细胞凋亡及改变干细胞因子亚型表达,在大鼠中引发不可逆的睾丸萎缩,且病情严重程度与给药速率相关。 Hexane-2,5-dione (250-500 mg/kg;灌胃;单次给药,每日 1 次,持续 15-21 天) 可对雄性 LAC Porton 大鼠的脑葡萄糖利用产生剂量依赖性抑制,且高剂量慢性给药会诱发明显的六碳化合物神经病变。
| Animal Model: |
Wistar rats (adult male, 400-500 g, with neurotoxicity) |
| Dosage: |
3.5 mmol/kg/day (17-day treatment); 2.5 mmol/kg/day (38-day treatment) |
| Administration: |
i.p.; 5 days/week; 17 days; 38 days |
| Result: |
Caused 27% body weight loss. Exhibited a mean neuropathy score of 5, corresponding to moderate to marked hindlimb paralysis. Induced numerous neurofilament-packed axonal swellings and scattered axonal degeneration in thoracic and lumbar spinal cord anterior fasciculi. Caused testicular damage including giant cell formation, spermatogenesis arrest, and pyknotic changes in Sertoli and germinal cell nuclei. Reached pyrrole adduct concentrations of 7.5 nmol/mg protein in serum, 3.7 nmol/mg protein in brain stem axonal cytoskeletal protein, and 4.7 nmol/mg protein in spinal cord axonal cytoskeletal protein for the 3.5 mmol/kg/day, 17-day group. Reached pyrrole adduct concentrations of 3.1 nmol/mg protein in serum, 1.7 nmol/mg protein in brain stem axonal cytoskeletal protein, and 2.2 nmol/mg protein in spinal cord axonal cytoskeletal protein for the 2.5 mmol/kg/day, 38-day group. Showed covalent crosslinking of axonal cytoskeletal protein of 6.4% in brain stem and 12.2% in spinal cord for the 3.5 mmol/kg/day, 17-day group. Showed covalent crosslinking of axonal cytoskeletal protein of 9.9% in brain stem and 11.6% in spinal cord for the 2.5 mmol/kg/day, 38-day group. |
| Animal Model: |
Sprague-Dawley rats |
| Dosage: |
2-6 mmol/kg/day |
| Administration: |
oral via drinking water; 3-5 weeks |
| Result: |
Altered assembly of purified testis tubulin starting 2 weeks after exposure. Decreased seminiferous tubule fluid formation by 3 weeks. Induced large, basally located Sertoli cell vacuoles in stages I, XII, XIII, and XIV as the first histopathological signs of injury, followed by sloughing and loss of germ cells by 4-5 weeks. Altered the cycle of the seminiferous epithelium, with decreased prevalence of certain stages and increased prevalence of others. Rendered seminiferous tubules devoid of differentiating germ cells but containing proliferating spermatogonia by 8-12 weeks after a 3-5 week exposure, with this atrophic state persisting for greater than 70 weeks post-exposure. Caused progressively more severe histopathological alterations in the testis with higher dose-rates, which positively correlated with the extent of microtubule assembly abnormality in purified testicular tubulin. Induced germ cell death via apoptosis, with DNA fragmentation ladders most prominent 5 weeks into exposure, and increased germ cell apoptosis detected as early as 2 weeks into treatment. Altered the ratio of soluble stem cell factor (sSCF) to membrane-bound stem cell factor (mSCF) in the testis, which correlated temporally with the onset of atrophy. Resulted in only 1% seminiferous tubule repopulation after 23 days of exposure, compared to greater than 90% repopulation in rats given depot GnRH agonist therapy for 10 weeks immediately post-exposure. |
| Animal Model: |
LAC Porton rats (male, 7-9 weeks of age at end of experimental periods) |
| Dosage: |
250; 500 mg/kg/day |
| Administration: |
i.g.; single dose (acute); daily for 15 days (high chronic); daily for 21 days (low chronic) |
| Result: |
Caused significant region-dependent decreases in cerebral glucose utilization in high-acute-dose group, with cortical regions, inferior colliculus, and hippocampus most affected, and decreased regional unidirectional glucose flux and permeability-surface area product for glucose influx relative to controls, with no significant changes in regional cerebral blood flow. Caused significant region-dependent decreases in cerebral glucose utilization in high-chronic-dose group, with inferior colliculus most affected, and significant increases in PS_in in thalamus, hypothalamus, and medulla-pons, with significant region-dependent increases in cerebral blood flow in thalamus, postcingulate cortex, and auditory cortex, and increased regional brain glucose contents relative to controls. Showed no significant changes in cerebral glucose utilization in low-chronic-dose group, but caused significant region-dependent changes in J_in and PS_in in substantia nigra, auditory cortex, superior colliculus, cerebellum, and medulla-pons. |
|